Comparing Chemotherapy Approaches for Advanced Ovarian Cancer
Author Information
Author(s): Inciura Arturas, Simavicius Andrius, Juozaityte Elona, Kurtinaitis Juozas, Nadisauskiene Ruta, Svedas Eimantas, Kajenas Skirmantas
Primary Institution: Kaunas University of Medicine
Hypothesis
What is the impact of neoadjuvant chemotherapy compared to adjuvant chemotherapy on clinical outcomes in patients with advanced ovarian cancer?
Conclusion
There was no difference in progression-free or overall survival between neoadjuvant and adjuvant chemotherapy groups despite the more extensive disease in the neoadjuvant group.
Supporting Evidence
- The median overall survival for neoadjuvant chemotherapy was 23.7 months.
- The median overall survival for adjuvant chemotherapy was 25.4 months.
- No significant difference in optimal cytoreductive surgery rates between treatment groups.
Takeaway
Doctors wanted to see if starting chemotherapy before surgery helps women with advanced ovarian cancer live longer, but it turns out it doesn't make a difference.
Methodology
Retrospective analysis of 574 patients treated with either neoadjuvant or adjuvant chemotherapy, comparing overall and progression-free survival rates.
Potential Biases
Potential selection bias due to the retrospective nature of the study.
Limitations
The study is retrospective and lacks randomized controlled trial data.
Participant Demographics
Patients with advanced ovarian cancer (FIGO stages III-IV) treated in four Lithuanian oncogynaecology departments.
Statistical Information
P-Value
p = 0.1310
Confidence Interval
[95% CI 668–769]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website